DPP IV Inhibitor Januvia First Out Of The Gate
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.
You may also be interested in...
Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.
Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.
Merck & Co. Executive Director Of Experimental Medicine Gary Herman: An Interview With “The Pink Sheet” DAILY
Firm’s head of experimental medicine talks about his mission to cut Merck’s R&D costs by failing earlier in the preclinical discovery process.